Remarks

This is intended to be a complete response to the official action mailed October 18, 2006 in which claims 17, 18, and 24-26 were rejected.

First Rejection under § 112 ¶1

Claims 17-18 and 24-26 stand rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement on the basis that the claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims have been amended herein to indicate that (1) the recombinant host cell is an "isolated" recombinant host cell, (2) the core 1-β3 galactosyl transferase "requires coexpression of a core 1 β3-galactosyl transferase specific molecular chaperone for configuring the core 1-β3 galactosyl transferase in an active form," and (3), the hybridization conditions in "B" are now "high stringency" conditions, as enabled and supported in the specification in ¶¶ 142, 144 and 145.

In view of the above, applicants respectfully submit the claims are now fully supported, described and enabled by the specification. The claim is now directed to host cells having only core 1 β3-galactosyl transferases which

require core 1 β3-galactosyl transferase specific molecular chaperone for activity.

In view of the above, applicants respectfully request reconsideration and withdrawal of the rejection under §112 ¶1.

Rejection under§ 102 (b)

Claims 17-18, and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Chen et al. (WO 00/15796 published on March 23, 2000).

The claims have been further amended to indicate that the first expressible polynucleotide and the second expressible polynucleotide are recombinant, as supported in ¶¶ 157, 102-110 and 122 and 40-44, and 49, for example. Chen et al. teach "293" cells which are asserted as comprising a gene encoding a core 1 β3-galactosyl transferase . The citation in Chen et al. indicated by the examiner as disclosing endogenous production of core 1 β3-GalT (p. 51, lines 4-5 of Chen et al.) cannot be found. In any event, Chen et al. do not teach a recombinant core 1 β3-galactosyl transferase in the 293 cell, nor would there be any motivation to introduce a recombinant core 1 β3-galactosyl transferase -encoding cDNA therein since until the disclosure of the present invention, chaperone the function of the protein having SEQ ID NO:1 or the gene having SEQ ID NO:2 was unknown.

In view of the above, applicants respectfully submit the present claims are not anticipated by (nor obvious over) Chen et al. under 35 U.S.C. §102(b), and request reconsideration and withdrawal of the rejection.

Conclusion

In view of the above, applicants respectfully submit the claims are now in a condition for allowance and respectfully issuance of a Notice of Allowance therefor.

Respectfully submitted,



Christopher W. Corbett, Ph.D.,
Reg. No. 36,109
DUNLAP CODDING & ROGERS, P.C.
P.O. Box 16370
Oklahoma City, Oklahoma 73113
Telephone: 405/607-8600
Facsimile: 405/607-8686
Agent for Applicants